Targeted Collaboration Leverage Cellecta's expertise in HT loss-of-function genetic screening, shRNA and CRISPR libraries, and NGS-based analysis to propose joint target discovery programs for biotech and pharma clients seeking novel therapeutic targets.

Expansion Opportunities capitalize on recent product launches such as DriverMap EXP and blood-based profiling capabilities to cross-sell integrated expression profiling services to translational research and biomarker discovery customers.

Biospecimen Synergy Position Tissue to Target collaborations with Cureline and related biospecimen services to offer end-to-end translational research workflows from tissue handling to molecular analysis, appealing to pre-clinical and translational labs.

Accessibility & Scale Highlight scalable, low-volume assays (e.g., dried blood microsamples) as attractive for clinical studies, remote sampling programs, or early-phase biomarker projects needing minimal material without compromising data depth.

SMB Growth Fit With revenue in the 10–25 million range and 11–50 employees, target mid-market biotech startups and academic-leaning biotech groups that require affordable, collaboration-friendly genetic screening and targeted profiling solutions.